RBC bolsters bank's healthcare offering with the acquisition of MDBilling.ca
Canadian medical billing leader helps physicians spend more time with patients and less time on paperwork & administration
TORONTO, Oct. 4, 2022 /CNW/ - Today, RBC announced it has acquired MDBilling.ca, a cloud-based platform that automates and simplifies medical billing for Canadian physicians. The company joins Dr.Bill at RBC, another leading medical billing company acquired by the bank in 2020.
Founded in 2008, Toronto-based MDBilling.ca's product offering is rooted in its best-in-class, proprietary software that supports physicians with their medical billing. As one of Canada's top digital medical billing solutions, MDBilling.ca is currently used by close to 9,000 Canadian physicians, with more than $2.3B in OHIP claims paid through the platform since inception. The company also boasts an extensive roster of partnerships with leading healthcare providers across Ontario.
Medical billing has always been tedious, stealing hours from a physician's work day and personal life due to a reliance on paperwork or antiquated technology and complex provincially-specific billing codes. MDBilling.ca's suite of products and services ensures physicians are able to spend less time doing paperwork so they can focus on what matters most, helping patients.
The acquisition supports RBC Healthcare's strategy to provide innovative solutions for physicians at every stage of their career journey. MDBilling.ca clients will also benefit from access to more than 1,100 RBC Healthcare Specialists trained to provide specialized advice and support for the unique financial needs of physicians and other healthcare professionals.
"Since the launch of our Healthcare practice, we have worked to make billing easier for physicians through RBCx's venture Dr.Bill. The acquisition of MDBilling.ca helps further this pursuit," says Sid Paquette, Head, RBCx. "We are proud to be a leader in medical billing in Canada, helping to simplify and expedite the process for physicians to get paid for the incredibly important work that they do."
Jaime Wong, co-founder and CEO, MDBilling.ca, added, "We couldn't be happier. This is a great opportunity for our employees and clients, as we move into our next phase of growth, backed by the strength of RBC."
The financial terms of the deal are not being disclosed.
MDBilling.ca is a cloud-based medical billing company servicing physicians in Ontario and British Columbia, through their mobile and web billing applications. Founded in 2008 and used by close to 9,000 physicians, the Toronto-based company is one of the largest medical billing companies in Ontario. Learn more at MDBilling.ca.
About RBCx
RBCx powers bold ideas, founders, and technology companies. We know building great businesses takes more than just finance, which is why our four pillars – Banking, Capital, Platform, and Ventures – combine to make us the go-to backer of Canadian innovation. We use our deep expertise to support businesses of all sizes and stages, and leverage RBC's extensive experience, networks, and capital to solve tomorrow's big problems.
About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 92,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada's biggest bank and one of the largest in the world, based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our 17 million clients in Canada, the U.S. and 27 other countries. Learn more at rbc.com.
We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/community-social-impact.
SOURCE RBC
Joint survey underscores critical need for a Canadian National Vision Health Strategy to address eye health issues
Canadian Ophthalmological Society and Canadian Association of Optometrists partner to support private member's bill to create a Vision Health Desk
TORONTO, Oct. 4, 2022 /CNW/ - In time for World Sight Day on October 13, the Canadian Ophthalmological Society and the Canadian Association of Optometrists have collaborated for the first time on a joint access research survey in the field of vision health. The survey is part of a continued partnership that will support the federal government's progress toward creating a national vision health strategy, identify gaps in the system and guide interventions in the future in an effort to coordinate and address eye health issues across the country.
While the survey revealed some issues related to eye care access, mostly driven by the pandemic, it also pointed to greater challenges, including a lack of understanding among Canadians about their eye health. Among those who did not visit an eye care professional in more than two years, over one-third (37 per cent) of respondents say the biggest reason is because they believe that there is nothing wrong with their vision. Meanwhile, in the past two years, two in five (41 per cent) Canadians have experienced or been diagnosed with one or more changes to their eye health which would necessitate a comprehensive exam, and points to a greater need for education about eye disease and vision loss.
"Despite blindness being the most feared disability for the large majority of Canadians, we're seeing a persistent lack of education about eye health, specifically around the major eye diseases which increase the risk of blindness without proper intervention," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society. "Vision loss carries significant costs on an individual level, but also to the public health purse. However, 75 per cent of visual impairment is avoidable if detected and treated early, while reducing government spending in the long run."
Canadians' familiarity with eye diseases
The survey findings reveal that Canadians need more education and awareness of eye health and eye diseases, to fully understand the importance of regular, comprehensive exams.
When it comes to Canadians' knowledge on the leading eye diseases, their awareness remains unchanged from last year's survey conducted by the Canadian Ophthalmological Society. Most are familiar (62 per cent) with cataracts, yet only one-quarter (27 per cent) of Canadians know that cataracts are the leading cause of blindness in the country. Less than half (47 per cent) are familiar with glaucoma (this number decreases to 37 per cent for younger Canadians aged 18-34). Meanwhile, only 39 per cent are familiar with age-related macular degeneration (AMD) which is the second leading cause of blindness, affecting nearly 2 million Canadians. Fewer are aware of diabetic retinopathy (22 per cent) and contact lens-associated dry eye disease (26 per cent).
"Blinding diseases affect older adults (55+) at much higher rates and as Canada's population ages, the number of individuals affected by vision impairment will rise," says Francois Couillard, Chief Executive Officer of the Canadian Association of Optometrists. "Given the importance of vision health and its effect on public health spending, the Government of Canada plays a critical role in developing vision health policies and all those involved in the delivery of eye health services have a role to play in supporting a successful outcome and pledges its ongoing collaboration to the realization of these objectives."
The survey findings underscore a critical need to create a National Vision Health Desk at the Public Health Agency of Canada that will develop and implement a National Vision Strategy. Last June the Honourable Judy Sgro, Member of Parliament for Humber River – Black Creek, introduced a Private Member's Bill, "An Act to establish a national strategy for eye care". The Vision Heath Desk would be responsible for the development and implementation of an evidence-based vision strategy that includes increased research funding, funding for public education and support, streamlining the approval process for new medicine and technology to treat/prevent vision loss, enhanced access to care for vulnerable populations, including Indigenous peoples, children, and seniors.
An online survey of 2003 Canadians aged 18+ was completed between June 10 and June 21, 2022, using Leger's online panel. No margin of error can be associated with a non-probability sample (i.e., a web panel in this case). For comparative purposes, though, a probability sample of 2003 respondents would have a margin of error of ±2.2%, 19 times out of 20. Leger's online panel has approximately 400,000 members nationally and has a retention rate of 90%.
About Canadian Ophthalmological Society
The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada. As eye physicians and surgeons, we are committed to assuring the provision of optimal medical and surgical eye care for all Canadians by promoting excellence in ophthalmology and by providing services to support our members in practice. Our membership includes over 900 ophthalmologists and 200 ophthalmology residents. We work collaboratively with government, other national and international specialty societies, our academic communities (ACUPO), our provincial partners and affiliates and other eye care professionals and patient groups to advocate for health policy in Canada in the area of eye and vision health. COS is an accredited, award-winning provider of Continuing Professional Development (CPD) through the Royal College of Physicians and Surgeons of Canada (RCPSC) and is an affiliate of the Canadian Medical Association (CMA). For more information, visit cos-sco.ca.
About Canadian Association of Optometrists
Optometrists are independent primary health care providers and represent the front line of vision health. Optometrists practice in a range of settings: most work in private practice, others work in clinics, hospitals, community health centres, corporate optometry, research, teaching and administration. The Canadian Association of Optometrists (CAO) is the national voice of optometry. Recognized at home and internationally as a leading advocate for the profession, it is dedicated to providing leadership and support to its +5700 members to enhance the delivery of healthy eyes and clear vision for all Canadians. For more information, visit www.opto.ca.
SOURCE Canadian Ophthalmological Society
Rogers Bank launches the Rogers Connections Mastercard to deliver customers more value
New cash back rewards card delivers unique benefits designed especially for Rogers customers
Cardholders receive five Roam Like Home days at no cost and a 30% Rogers redemption bonus
TORONTO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Rogers Bank today announced the launch of the new Rogers Connections™ Mastercard®, the latest in the company’s reward-rich suite of credit card options for Canadians. The new card delivers cash back rewards and tangible Rogers benefits, reaffirming Rogers commitment to providing innovative products and value to Rogers customers.
With the Rogers Connections Mastercard, Rogers Wireless customers can stay connected while travelling with five Roam Like Home™ days at no cost every year, just in time to help cardholders get more out of the winter travel season. This first-of-its-kind card benefit – available for travel in more than 185 destinations – provides up to $75 value each year and is only available from Rogers Bank.
Rogers Connections Mastercard cardholders also earn cash back on their everyday purchases, helping customers stretch their spending as rising prices put pressure on the consumer budget. Cardholders will earn 2% unlimited cash back on eligible U.S. dollar purchases and 1% unlimited cash back on other eligible purchases. Customers who apply today for the Rogers Connections Mastercard will get a welcome bonus of 10% cash back on all purchases for the first three months, up to a value of $100. Rogers customers can make their cash back rewards go even further with a 30% bonus on the earned cash back value when redeemed for Rogers phone upgrades, accessories, or to cover their monthly Rogers bill.
“At Rogers, we are wholeheartedly dedicated to delivering innovative products and services that enhance our customers’ experiences,” said Lisa Durocher, CEO, Rogers Bank and EVP, Financial and Emerging Services at Rogers Communications. “Our new Rogers Connections Mastercard is designed to unlock even more value for Rogers customers, rewarding cardholders with benefits that no other card can provide.”
The card has no annual fee for the first year. After the first year, the annual fee is $29, however the card provides an ongoing annual fee rebate if customers pay their monthly Rogers bill online with their Rogers Connections Mastercard.
The Latest Offering from Rogers Bank
The Rogers Connections Mastercard is the newest product from Rogers Bank, which has been delivering innovative credit cards to Canadians since 2013. Rogers Bank’s products and services are designed to maximize value for Rogers customers and provide ultimate flexibility, helping customers turn their everyday spending into infinite possibilities.
Rogers Bank credit card products are simple and easy to use, powered by the Rogers Bank App, helping customers manage their spending and accounts on the go, and allowing them to instantly redeem for rewards. Customers can also manage their finances and cashflow through Rogers Bank’s equal payment program for big ticket purchases.
Rogers Bank credit cards come with layers of security features, like transaction monitoring, alerts, and the benefit of zero liability in the event of unauthorized use, while also offering features like travel insurance on select cards and the ability to purchase optional balance protection to provide extra peace of mind.
Rogers Bank is a wholly owned subsidiary of Rogers Communications Inc. For more information on the Rogers Connections Mastercard and complete terms and conditions, please visit: www.RogersBank.com/Connections.
About Rogers Communications Inc. Rogers is a leading Canadian technology and media company that provides communications services and entertainment to consumers and businesses. Rogers shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit: www.rogers.com or http://investors.rogers.com.
The Happy Clam Treads New Waters in Search of Harmonious Life
Boston, October 5, 2022 — Like clams finding nourishment from filter feeding, Rosemary Schmidt derives strength from taking in the bits and bytes of information swirling all around her and weaving it into a cohesive mosaic. Putting thoughts and ideas into a logical sequence that tells a story helps her make sense of a sometimes senseless world.
“It’s as satisfying as kneading and shaping a bread dough,” she writes in the introduction to her latest book, The Happy Clam. “It’s both an itch and a need. What’s inside needs to be put in order.”
The Happy Clam is a direct reflection of how Schmidt approaches life — by using the parts and pieces to form a cohesive whole. And it’s in that wholeness where harmony is possible, Schmidt posits.
Weaving research from the fields of sociology, psychology and neurology with deeply personal, relatable anecdotes, Schmidt contemplates what brings people joy, how change happens and what makes people tick.
The first half of the book lays the groundwork, ruminating on the benefits of being happier and why it is a worthwhile goal, and the myriad subtle but deliberate changes people can make to move the needle a tick or two.
The second half pivots to a more narrative style, as Schmidt shares stories related to her time as a supervisor, the sudden loss of her sister, and her mother’s gradual decline and eventual passing. In its final chapters, the book takes a more philosophical and theological turn, getting at the heart of human relationships and how to make change happen.
“Without telling you what to do, The Happy Clam offers a roadmap and allows you to chart your own course,” Schmidt adds. “It will make you think and leave you smiling.”
About the Author
Rosemary A. Schmidt is a Boston-area author, blogger and geologist. She published her first book, Go Forward, Support! The Rugby of Life, in 2003, which explores life lessons drawn from the sport of rugby.
Schmidt holds a Bachelor of Science degree in geology from the University of Dayton and a Master of Science in geology from the University of Illinois. She works as a professional geologist. Originally from the Chicago area, Schmidt now resides near Boston with her spouse, Susan.
Visit her blog at www.happyclam.net, or follow her on Twitter at @GainlineRS.
The Happy Clam
Publisher: Gainline Press
ISBN-10: 0970852827
ISBN-13: 978-0970852823
Available from Amazon.com, BN.com, and many other online sellers and independent bookstores
###
WELLPATH COLLABORATES WITH HI-BRIDGE HIE AND MOREHOUSE SCHOOL OF MEDICINE TO PROVIDE IMPROVED CARE DELIVERY FOR GEORGIA CORRECTIONAL PATIENTS
NASHVILLE, Tennessee – Wellpath recently announced an alliance with the Morehouse School of Medicine and the HI-BRIDGE Health Information Exchange (HIE) to electronically share real-time correctional patient health information for care delivery throughout 70 facilities in Georgia. This alliance enables the exchange of real-time, secure healthcare data between the HIE and Wellpath’s electronic health record platform, Electronic Records Management Application (ERMA). The data can include medication history, prior diagnoses, allergies, and lab reports from any one of the many contributing sources. The bi-directional data flow between Wellpath and HI-BRIDGE HIE also enables clinical services provided by Wellpath to be added to the patient record and shared with other local and national healthcare providers and organizations when the patient seeks medical care following release. “Communication is crucial as it relates to healthcare delivery in our facilities and incorporating this model will help ensure information is being shared efficiently and in real-time,” said Georgia Department of Corrections Commissioner Timothy C. Ward. “We appreciate our partners at Wellpath and their commitment to continuous process improvement involving healthcare for our offender population.” The HI-BRIDGE HIE is an independent regional information exchange established through the National Center for Primary Care at Morehouse School of Medicine and connected to the Georgia Health Information Network (GaHIN). The simplified exchange of comprehensive, real-time patient health information supports care coordination and optimal health outcomes by eliminating disparities and improving access to health information. The Wellpath/HI-BRIDGE HIE relationship goes back to 2017, connecting a network of local county jails with the exchange of patient health information. “This is a unique model of data exchange partners covering public, private, and academic experts,” said Carmen L. Hughes, MBA, executive director, HI-BRIDGE HIE. “Through the partnership, Wellpath clinicians will have patient clinical records at the point of care or in a healthcare crisis; this is critical for continuity of patient care,” Hughes said. Wellpath continuously seeks ways to improve the quality of healthcare delivered to its patients. “Health Information Exchanges are an important component in the delivery of quality healthcare, and we believe our patients are best served when we provide them with the most informed care possible,” said Jorge Dominicis, CEO of Wellpath. “When one of our healthcare professionals meets a patient for the first time and immediately has access to the patient’s entire medical history, that patient can receive optimal care, and that is always our goal.” Wellpath expanded its relationship with Morehouse School of Medicine in November 2021 by helping to offer an Online Education and Expanded Programs (OEEP) certificate that promotes health equity for justice-involved individuals. Wellpath clinicians are helping build another course on the impact of social determinants of health (SDoH) in correctional settings, with the goal to encourage community resources that eliminate barriers to care for justice-served patients. “This special relationship in education between Wellpath and Morehouse began in November 2021 when the two organizations recognized the need for medical programs focused on incarcerated patients,” explained Dominic H. Mack, MD, MBA, executive medical director, HI-BRIDGE HIE, director, National Center for Primary Care, and faculty member for Family Medicine, at the Morehouse School of Medicine. “Together, we designed a self-directed online certificate for coaches wanting to help justice-involved individuals. Technology plays a significant role in primary care practice,” said Dr. Mack. Students with a bachelor’s degree are guaranteed admission into Morehouse School of Medicine, pending SACSCOC approval of a Master of Administration in Justice-Involved Care (MAJIC) degree program. They also receive a scholarship, he said. ###ABOUT WELLPATHWellpath is the premier provider of localized, high-quality, compassionate care to vulnerable patients in challenging clinical environments. Wellpath holds patients at the center of everything we do and promotes rigorous standards of care and innovation. With over 14,200 clinicians and professionals in 36 states across the U.S. and Australia, Wellpath provides medical and mental healthcare services for over 240,000 patients daily in more than 550 facilities, including prisons, jails, state hospitals, forensic treatment, civil commitment centers, and community care centers. Learn more at www.wellpathcare.com. ABOUT MOREHOUSE SCHOOL OF MEDICINEFounded in 1975, Morehouse School of Medicine (MSM) is among the nation’s leading educators of primary care physicians, biomedical scientists, and public health professionals. An independent and private historically Black medical school, MSM was recognized by the Annals of Internal Medicine as the nation’s number one medical school in fulfilling the creation and advancement of health equity. MSM faculty and alums are known for excellence in teaching, research, public policy, and exceptional patient care. The Commission accredits MSM on Colleges of the Southern Association of Colleges and Schools to award doctoral and master’s degrees. To learn more about programs and donate today, please visit www.msm.edu or call 404-752-1500. ABOUT THE HI-BRIDGE HEALTH INFORMATION EXCHANGE (HIE)HI-BRIDGE HIE is an independent regional exchange established through the National Center for Primary Care at Morehouse School of Medicine and connected to the Georgia Health Information Network (GaHIN). The regional exchange, based in Atlanta, provides interoperability through integrated technology and clinical support service to meet the needs of smaller practices, health systems, and other providers of healthcare delivery for the electronic exchange of patient clinical information. Wellpath / 3340 Perimeter Hill Drive / Nashville, TN 37211 www.wellpathcare.com
Alimentiv, Satisfai Health, and Virgo Announce Partnership to use AI-driven technology to Enhance Clinical Trials in IBD and other GI Diseases
The partnership enables advanced AI-fueled HD video capture, decision support, and clinical research tools for Alimentiv's global clinical trial investigator site network.
LONDON, ON, Oct. 5, 2022 /CNW/ - Alimentiv Inc. ("Alimentiv"), Satisfai Health, Inc ("Satisfai"), and Virgo Surgical Video Solutions, Inc. ("Virgo") today announced a strategic partnership to revolutionize central reading, data capture, decision support, and patient recruitment in the clinical trial domain for Inflammatory Bowel Disease (IBD) and allied GI conditions. Satisfai, a global leader in developing artificial intelligence solutions for gastroenterology, and Virgo, an industry leader in endoscopy video capture technology, will leverage their combined strengths to work in partnership with Alimentiv, a leading CRO in gastroenterology, to realize the full potential of AI-powered precision imaging in the GI clinical trials space.
"This synergy of Satisfai and Virgo with Alimentiv is a positive development for patients with IBD and the drug development space. Clinical trials have many pain points, and this strategic partnership will enable advances in improving the efficiency of clinical trials and make some significant changes to how trials are run", said Jeff Smith, CEO of Alimentiv. "We are delighted to enter this arrangement to bring the next generation of imaging technology to clinical trials in gastroenterology."
"Artificial Intelligence in medicine is being increasingly adopted across various clinical specialties, with gastroenterology being one key field of use, particularly endoscopy," said Dr. Michael Byrne, CEO and founder of Satisfai Health, Clinical Professor of Medicine and gastroenterologist in Vancouver. "Working with Virgo, we are excited to bring AI-driven solutions to the IBD clinical trials arena. To be able to do so with Alimentiv — a leading Gastroenterology and imaging CRO—is a great opportunity. Our clear ambition is to change the clinical trial paradigm for IBD and other disease states such as Eosinophilic Esophagitis. As three groups working together, we are confident we can do so."
"Combining Satisfai's marquis AI solutions with Virgo's HIPAA and SOC 2 compliant automated cloud video capture technology and Alimentiv's 21CFR11 compliant solutions, expansive site community, and imaging expertise is very powerful. We truly look forward to realizing this vision and bringing real-time, in-line AI solutions to GI clinical trials worldwide," said Matthew Schwartz, CEO and co-founder at Virgo.
This partnership will facilitate Alimentiv's continued leadership in GI Clinical Trials through exclusive access to Satisfai's SmartScore Central Reading tool and Virgo's fully integrated, hands-free, cloud-based high-definition video-capture fleet. In addition, this will provide pharmaceutical and biotech sponsors with access to the ongoing development of novel endpoints, scoring methodologies, and scalable solutions geared toward bringing novel therapies to market faster.
About Alimentiv Inc. Alimentiv is a global contract research organization (CRO) providing clinical trials, central image management, precision medicine, and real-world evidence services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. The organization's unique model combines the efforts of internationally recognized academic researchers and operational experts to offer integrated solutions to customers. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, central image management solutions, outcome measure development, and precision medicine for drug development in IBD. Today, Alimentiv provides services in more than 50 countries worldwide, collaborates with leading universities and academic institutions across the globe, and partners with many leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients. Alimentiv is committed to investment in medical research and development, focusing on identifying barriers to drug development and pursuing solutions that advance IBD research. The research findings are operationalized into an efficient clinical trial methodology for clients that aligns with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation, and standardization of outcome measures and technology, shaping the evolving clinical trial landscape for multiple indications and providing meaningful long-term consequences for patients, their treatment, and society. For more information, visit: www.alimentiv.com
About Satisfai Health Satisfai is a leading medical solutions provider specializing in AI applications applied to large addressable markets in gastroenterology. Satisfai's solutions deliver real-time medical imagery analysis, providing clinicians with decision support intelligence that dramatically improves patient outcomes. Satisfai is supported by a highly respected board of medical clinicians and key opinion leaders who operate at the top of their fields in the many areas of gastroenterology. Satisfai enjoys a strong voice on academic panels, leading GI societies, and direct access to prominent industry players seeking to adopt new AI technologies in gastroenterology. For more information, visit www.satisfai.health or email andrew@satisfai.health
About Virgo Virgo provides the leading cloud video capture, management, and artificial intelligence analysis platform for endoscopic medicine. Academic, integrated, and private practice healthcare providers use the Virgo platform to advance patient care through video-based research and training initiatives. Since launching, Virgo has helped physicians capture over 400,000 endoscopy procedures using industry-leading HIPAA, HITRUST, and SOC 2-compliant cloud service providers. Virgo also supports integration with all leading electronic health records systems. In 2021, Virgo launched a suite of tools called VirgoTrials, which help pharmaceutical trial sponsors and their participating trial sites accelerate patient recruitment and shorten the overall enrollment period for trials. For more information, visit www.virgosvs.com or email jake@virgosvs.com
SOURCE Alimentiv Inc.
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
Grant of US patent strengthens the PharmaTher’s intellectual property portfolio covering novel uses and delivery forms of ketamine
Announced positive efficacy and safety data from Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients, with 100% of patients treated with ketamine demonstrating a reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale showing a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41% at 3-month (p=0.011) post-ketamine
Planning a Phase 3 clinical study to allow for FDA approval of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the United States Patent and Trademark Office (“USPTO”) granted US Patent No: 11,426,366, titled “Compositions and Methods for Treating Motor Disorders,” which includes claims intended to cover ketamine in the potential treatment of Parkinson’s Disease and motor disorders that cause involuntary or uncontrollable movement or actions of the body (the “Patent”).
Fabio Chianelli, CEO of PharmaTher, commented: “We are pleased with the USPTO grant of the patent covering ketamine in the treatment of Parkinson’s disease and motor disorders. The US patent strengthens our intellectual property portfolio covering novel uses and delivery forms of ketamine. We are advancing the clinical development of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, and we are seeking FDA agreement on pursuing approval under the 505(b)(2) regulatory pathway with a potential Phase 3 clinical study.”
On September 16, 2022, the Company announced positive efficacy and safety data from a Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia (“LID”) in Parkinson’s disease via a late-breaking abstract presentation, titled “Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia” at the MDS International Congress of Parkinson's Disease and Movement Disorders®.
The Phase 1/2 study was an open-label, dose-finding trial to test the safety, tolerability and pharmacokinetics of low-dose ketamine infusion to treat levodopa-induced dyskinesia in Parkinson’s disease and to find an effective dose-range suitable for outpatient use. Two 5-hour low-dose ketamine infusions were given within a one-week period. The clinical study outcomes measured reduction of dyskinesia, captured with the Unified Dyskinesia Rating Scale (“UDysRS"), and effects on parkinsonian symptoms, captured with the Unified Parkinson's Disease Rating Scale (“UPDRS”).
The study enrolled 10 subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr. These data highlight that ketamine was safe, well-tolerated, and demonstrated that 100% of subjects treated with ketamine had a reduction in dyskinesias as measured by UDysRS indicating possible efficacy with a large effect size that warrants further investigation in a pivotal Phase 3 clinical study. UDysRS showed a clinically meaningful reduction from baseline through 3 months.
Infusion 2
3-weeks post Infusion
3-months post Infusion
UDysRS Percent Reduction
51% (p=0.003)
49% (p=0.006)
41% (p=0.011)
UPDRS Percent Reduction
27% (p=0.057)
28% (p=0.026)
5% (p=0.258)
The maximum tolerated infusion rate ranged from 0.20-0.30 mg/kg/hr which was dependent on either discomfort due to dissociation or hypertension. There were no adverse events post-infusion. Analyses of the patient diaries and the pharmacokinetic data are ongoing.
Based on these data, the Company is preparing to engage the FDA to establish the next steps for a planned Phase 3 clinical study to allow for the Company’s proprietary ketamine intravenous product, KETARX™, approval for Parkinson’s disease under the 505(b)(2) regulatory pathway. In August 2020, the Company entered into an exclusive license agreement with the University of Arizona to develop and commercialize the Patent.
Ketamine’s Potential In Parkinson’s Disease
Parkinson’s disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide. The global Parkinson’s disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 2025 [360iResearch 2020] and it is estimated that the potential market opportunity for LID Parkinson’s disease to be over USD $3 billion in the U.S. alone.
Ketamine is an FDA-approved N-methyl-D-aspartate receptor-modulating (NDMA) drug that is widely used as an anesthetic agent either alone or in combination with other anesthetic agents [Smith et al, 1987; Pacheco et al, 2014]. The possible therapeutic effect of low-dose ketamine on levodopa-induced dyskinesia was noted in a retrospective analysis of Parkinson’s disease patients who received ketamine for pain relief. During this analysis, it was observed that the patients experienced an improvement in LID lasting several weeks beyond treatment [Sherman et al, 2016]. These results were corroborated in a test of low-dose ketamine in a rodent LID model, and this possible effect has also been examined in a controlled study [Bartlett et al, 2016]. Ketamine may also have additional benefits in the treatment of pain [Niesters et al, 2014] and depression [Diamond et al, 2014; Murrough et al, 2013], which are frequent comorbidities of Parkinson’s disease.
About Parkinson’s Disease
There is currently no cure for Parkinson’s disease, although some drug combinations are used to treat the disease symptoms. Although the etiology of Parkinson’s disease is not fully understood, it is thought to result from loss of pigmented dopaminergic neurons in the Substantia nigra and their striatal projections, leading to dopamine deficiency in the striatum [Schapira and Jenner, 2011]. This ultimately affects the cortico-striatal system that controls movement. As a progressive neurogenerative disorder of the central nervous system that primarily affects the motor nerve system, symptoms of Parkinson’s disease may emerge slowly and include tremors, rigidity, bradykinesia, and postural instability [Paulson and Stern, 2004]. Also, patients may experience non-motor symptoms such as autonomic dysfunction (orthostatic hypotension, constipation, bladder dysfunction), psychiatric (depression), cognitive and sensory symptoms (pain) [Olanow, et al, 2009]. These non-motor symptoms become more common as the disease progresses. Treatments, including levodopa and dopamine agonists, which restore the dopamine deficits in the brain, have been employed for almost 50 years. However, with continued treatment using levodopa, dose-limiting motor side-effects often emerge. This includes the emergence of abnormal involuntary movements termed Levodopa Induced Dyskinesias, which can be identified in about 50% of patients within five years after initiation of levodopa treatment and in almost all patients within ten years post-treatment initiation. These side effects often limit further dose increases in dopaminergic therapy.
There can be no assurance that the FDA will support any potential request for an expedited path to approval or further development for ketamine in the treatment of Parkinson’s disease.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders. PharmaTher’s product portfolio consists of KETARX™ (ketamine) delivered by intravenous injection, intradermal microneedle patch, and subcutaneous pump administration. Learn more at PharmaTher.com.
Expert Shares Essential Traits of Strategic, Effective Leadership
Dallas, TX, October 5, 2022 — Some people actively pursue leadership positions, while others have the responsibility thrust upon them. Whatever the case, effective leadership is always in short supply, even though many people hold positions that require it, according to consultant Mark Rapier.
“Your personal leadership journey will not be a straight line to success,” Rapier said. “You will need to ebb and flow when you find yourself in those leadership moments, being prepared with expanded views.”
His new book,The Leader With a Thousand Faces: A Personal Study of Leadership,
describes the journey that leaders must learn how to navigate and aims to give readers perspectives to consider before they find themselves needing answers. Written from Rapier’s experience, not theory, readers will find the clues to uncovering the best versions of the leaders they choose to be.
Rapier explores leadership types (including some interesting combos), dispels myths and then gets into the nitty gritty of day-to-day leadership duties. Readers will also find situational examples, self-evaluation tools and answers to common questions, such as:
- What is the difference between good leaders and those who just think they are? - What is the difference between management and leadership? - Why do some techniques used successfully in the past no longer work? - How can those in leadership roles demonstrate that they are ready for more leadership responsibilities?
- And much more.
“Leadership is in all of us,” Rapier added. “All we need to do is unlock our potential.”
About the Author
Over more than 40 years, Mark Rapier has acquired skills and experiences across multiple industries and platforms, which has given him valuable perspectives. As an adviser, Rapier works with C-suites, IT leadership and business stakeholders to develop and execute effective digital transformation strategies and IT operating models. He has experience with the automotive, financial services, insurance, life sciences, logistics, retail, utilities and U.S. public sectors, and has worked with global organizations with revenues ranging from $300M to $160B.
He has worked with hundreds of leaders from all over the world and led global organizations with more than 1,500 team members. He drew upon this experience and extensive research to inform The Leader With A Thousand Faces.
Newborn’s First 1,000 Days Crucial to Preventing Diseases, Allergies — New Book
Philadelphia, October 5, 2022 — Expectant moms are advised to eat well, exercise, take vitamins, abstain from caffeine and do everything possible to ensure the optimal health of their babies. Yet, children born today are sicker than in any past generation. Food allergies, asthma and other chronic health conditions affect up to 30 percent of kids across the country. Why?
In The Baby and the Biome: How the Tiny World Inside Your Child Holds the Secret to Their Health (Avery, an imprint of Penguin/Random House; September 6, 2022; Hardcover; ISBN: 9780593421024), author Meenal Lele reveals the answer—and it’s not bad genes or bad parenting. As a medical researcher with a chemical engineer’s degree from Wharton, her firsthand experience as an “allergy mom,” Lele sheds light on the key role of a newborn’s microbiome (the mix of bacteria, fungi, and viruses that live on us and in us) in either preventing or provoking diseases of the immune system, which include not only food allergies and asthma but also eczema, ADHD, IBS, type 2 diabetes, Crohn’s disease and more.
“Immune disease needs a revolution in thinking—and an accessible way for parents to understand it,” Lele asserts. Interweaving the story of her firstborn son Leo’s life-threatening struggles with food allergies and asthma with significant, potentially life-saving scientific findings, Lele aims to lead that revolution by educating parents about how to prioritize and strengthen their baby’s microbiome by protecting the delicate skin, gut and lung barriers.
In accessible language and a reassuring tone, The Baby and the Biome combines medical insights with practical advice on a more informed, healthier approach to the ABCDEs—Antibiotic use, Baby Care, Diet and Environment—during a newborn’s first thousand days, and helps parents raise kids in this toxin-filled world. You’ll learn:
- How to nurture your baby’s biome during pregnancy, practice good biome care from the moment of birth and, if possible, choose breastfeeding over formula to support immunity—but only exclusively for the first two months of your baby’s life.
- Why many standard practices endorsed by pediatricians—wash your baby daily, wait three days between introducing your baby to new foods and more—are not backed by science and might actively hurt your child’s immune defenses.
- Why eczema, which affects about 25 percent of infants, is not just “a little rash” but both a serious warning sign and direct cause of increasingly worse immune conditions to come—plus, clinically proven, actionable ways to treat it.
- Why antibiotics commonly prescribed for ear infections and fever are often unnecessary and can actually make a child sick longer and cause diarrhea, among other complications—plus, examples of when antibiotics are essential.
- Why to avoid using creams and lotions, including sunscreen, on your baby’s skin—and tips for minimizing diaper rash, including using cloth diapers (which are also better for the environment than super-absorbent disposable diapers).
- Why giving your baby regular exposure to the most common food allergens, including peanuts and eggs, is a vital practice for developing a healthy, disease-free immune system—and how to do it safely and stress-free.
- The importance of feeding your baby a good and diverse diet, with priority on avoiding added sugar and processed foods, which contain preservatives, dyes, synthetic fats and emulsifying agents that are poisonous to the gut barrier.
- The biome-friendly benefits of letting your baby play and crawl around in good dirt, whether in your own backyard or a natural park with real grass, trees and mud, as opposed to a playground built on artificial turf.
- Tips for cleaning your home, dishes and clothes, as well as your family’s hair and bodies, to prevent immune disorders—plus, the potential long-term dangers of our national obsession with antibacterial cleansers … and much more.
About the Author
Meenal Lele is a mom to two boys, medical researcher and chemical engineer with a degree from the Wharton School. She is the founder and CEO of Lil Mixins, a company devoted to educating parents about how to prevent their children from developing food allergies. She lives in Philadelphia, PA, with her family.
From Homeless to the C-Suite: CEO Traces Improbable Journey in The Most Unlikely Leader
West Palm Beach, FL, October 5, 2022 — At age 15, Roger Smith dropped out of school, left home and became addicted to drugs. By all accounts, he should have hit rock bottom multiple times before that fateful day, nearly 20 years later, when he found himself on his hands and knees, rummaging for remnants of crack cocaine in the carpet. It’s an image of himself he says he never wants to recreate.
“The picture of who I was at the very end — that picture was so strong in my mind that I just never wanted to go back there again,” Smith said during a recent interview.
The Most Unlikely Leader: An Unbelievable Journey From GED to CEO is Smith’s empowering story of how he got clean, got his act together and rose through the ranks of American Income Life Insurance, where he eventually became CEO. But Smith didn’t stop there. He also went on to serve as CEO of National Income Life Insurance and Liberty National Life Insurance companies.
A fast-paced blend of memoir, business manifesto and leadership manual, The Most Unlikely Leader is an unflinching look at a side of Smith’s life that few people knew about — until now. He takes readers inside his philosophy, his decisions (both good and bad) and the sheer grit he harnessed to overcome seemingly insurmountable obstacles.
Smith speaks candidly about his struggles with addiction, divorce, lack of formal education and homelessness in an effort to show readers that problems can be solved, bad habits can be broken, and challenges can be overcome with the right mindset and work ethic.
“I want to share my story to tell you that your life and your career and who you are as a person are all within your hands,” he wrote in the book’s introduction. “You can fall all the way down to a dark place where you can’t see your way out … and then through sheer grit and gumption and tenacity … you can claw your way out. Because that’s what I did.”
About the Author
Roger Smith is an American author and former CEO of American Income Life Insurance, National Income Life Insurance and Liberty National Life Insurance companies. His journey is one that embodies the fact that no matter how low a person is in life, almost anything is possible with determination and the right mindset. He was the recipient of the Yitzhak Rabin Legacy Award, Eleanor Roosevelt Human Rights Award, Healthcare For All Champion Award, Sol Stein Award and numerous others. He is the father of five adult children (Nicole, Conrad, Emily, Adam and Amiah), proud grandfather of Maggie Mae, and currently resides in Florida with his wife, Demi, and his two dogs, Penelope and Chrome.
Wellpath / 3340 Perimeter Hill Drive / Nashville, TN 37211 
